Targeting of cathepsin S reduces cystic fibrosis-like lung disease.

Saved in:
Bibliographic Details
Title: Targeting of cathepsin S reduces cystic fibrosis-like lung disease.
Authors: Small DM; Airway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.; These two authors contributed equally to this work., Brown RR; Airway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.; These two authors contributed equally to this work., Doherty DF; Airway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK., Abladey A; Airway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK., Zhou-Suckow Z; Dept of Translational Pulmonology, Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), University of Heidelberg, Heidelberg, Germany., Delaney RJ; Airway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK., Kerrigan L; Airway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK., Dougan CM; Airway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK., Borensztajn KS; INSERM UMRS_933, Université Pierre et Marie Curie, Hôpital Trousseau, Paris, France., Holsinger L; ViroBay Inc., Menlo Park, CA, USA., Booth R; ViroBay Inc., Menlo Park, CA, USA., Scott CJ; Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK., López-Campos G; Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK., Elborn JS; Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.; Respiratory Medicine, Imperial College and Royal Brompton Hospital, London, UK., Mall MA; Dept of Translational Pulmonology, Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), University of Heidelberg, Heidelberg, Germany.; Dept of Pediatric Pulmonology and Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.; Berlin Institute of Health (BIH), Berlin, Germany., Weldon S; Airway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK., Taggart CC; Airway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.
Source: The European respiratory journal [Eur Respir J] 2019 Mar 28; Vol. 53 (3). Date of Electronic Publication: 2019 Mar 28 (Print Publication: 2019).
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: European Respiratory Society Country of Publication: England NLM ID: 8803460 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 1399-3003 (Electronic) Linking ISSN: 09031936 NLM ISO Abbreviation: Eur Respir J Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1399-3003
DOI:10.1183/13993003.01523-2018